EA201791560A1 - Порошковый состав для интраназального введения для лечения гипогликемии - Google Patents

Порошковый состав для интраназального введения для лечения гипогликемии

Info

Publication number
EA201791560A1
EA201791560A1 EA201791560A EA201791560A EA201791560A1 EA 201791560 A1 EA201791560 A1 EA 201791560A1 EA 201791560 A EA201791560 A EA 201791560A EA 201791560 A EA201791560 A EA 201791560A EA 201791560 A1 EA201791560 A1 EA 201791560A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hypoglycemia
powder composition
intranasal administration
treatment
provides
Prior art date
Application number
EA201791560A
Other languages
English (en)
Other versions
EA034820B1 (ru
Inventor
Санкарам Б. Мантрипрагада
Клод А. Пиш
Бетцбрюгге Джо Ян Филип Ван
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55538593&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201791560(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201791560A1 publication Critical patent/EA201791560A1/ru
Publication of EA034820B1 publication Critical patent/EA034820B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0043—Non-destructive separation of the package, e.g. peeling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/073—Syringe, piston type

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

В настоящем изобретении предложен порошковый состав, содержащий глюкагон или аналог глюкагона, для интраназального введения, подходящий для лечения гипогликемии и, в частности, для лечения тяжелой гипогликемии. В настоящем изобретении также предложен способ получения указанного порошкового состава и устройства и способы применения порошкового состава.
EA201791560A 2015-02-17 2016-02-16 Порошковый состав для интраназального введения для лечения гипогликемии EA034820B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562117031P 2015-02-17 2015-02-17
PCT/US2016/018003 WO2016133863A1 (en) 2015-02-17 2016-02-16 Nasal powder formulation for treatment of hypoglycemia

Publications (2)

Publication Number Publication Date
EA201791560A1 true EA201791560A1 (ru) 2018-02-28
EA034820B1 EA034820B1 (ru) 2020-03-25

Family

ID=55538593

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791560A EA034820B1 (ru) 2015-02-17 2016-02-16 Порошковый состав для интраназального введения для лечения гипогликемии

Country Status (41)

Country Link
US (3) US10213487B2 (ru)
EP (3) EP3673900A1 (ru)
JP (3) JP6522144B2 (ru)
KR (1) KR102121443B1 (ru)
CN (1) CN107278154B (ru)
AU (2) AU2016220235B2 (ru)
BR (1) BR112017014994B1 (ru)
CA (1) CA2975562C (ru)
CL (1) CL2017002031A1 (ru)
CO (1) CO2017008148A2 (ru)
CR (1) CR20170373A (ru)
CY (1) CY1122716T1 (ru)
DK (1) DK3258919T4 (ru)
DO (1) DOP2017000179A (ru)
EA (1) EA034820B1 (ru)
EC (1) ECSP17053843A (ru)
ES (1) ES2775498T5 (ru)
FI (1) FI3258919T4 (ru)
GT (1) GT201700179A (ru)
HR (1) HRP20200222T4 (ru)
HU (1) HUE049413T2 (ru)
IL (1) IL253273B (ru)
LT (1) LT3258919T (ru)
MA (3) MA52253A (ru)
MD (1) MD3258919T3 (ru)
MX (1) MX2017010572A (ru)
MY (1) MY175669A (ru)
NZ (1) NZ734035A (ru)
PE (1) PE20171334A1 (ru)
PH (1) PH12017501486A1 (ru)
PL (1) PL3258919T5 (ru)
PT (1) PT3258919T (ru)
RS (1) RS59918B2 (ru)
SA (1) SA517382068B1 (ru)
SG (1) SG11201705640PA (ru)
SI (1) SI3258919T2 (ru)
SV (1) SV2017005515A (ru)
TN (1) TN2017000349A1 (ru)
UA (1) UA121874C2 (ru)
WO (1) WO2016133863A1 (ru)
ZA (2) ZA201704944B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3258919T3 (ro) * 2015-02-17 2023-04-30 Lilly Co Eli Formulare de pulbere nazală pentru tratamentul hipoglicemiei
US11013873B2 (en) * 2017-01-06 2021-05-25 HealthPartners Institite Methods for treating patients with impaired awareness of hypoglycemia
AU2018319592B2 (en) 2017-08-20 2024-06-27 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
JP2020534333A (ja) 2017-09-21 2020-11-26 ザ スクリプス リサーチ インスティテュート 慢性副鼻腔炎を処置および防止するための新規治療
TWI771669B (zh) 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
IL295977A (en) 2020-03-16 2022-10-01 Zealand Pharma As Liquid formulations of glucagon analogs
MX2022014216A (es) 2020-05-18 2022-12-07 Orexo Ab Nueva composicion farmaceutica para administracion de farmacos.
KR20240103005A (ko) 2021-11-25 2024-07-03 오렉쏘 에이비 아드레날린을 포함하는 약학적 조성물

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58189118A (ja) * 1982-04-30 1983-11-04 Takeda Chem Ind Ltd 経鼻投与製剤
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
US5059587A (en) 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
PT88490B (pt) * 1987-09-14 1992-11-30 Novo Nordisk As Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
DK49791D0 (da) * 1991-03-20 1991-03-20 Novo Nordisk As Nasalt pulverpraeparat
DE19518810A1 (de) 1995-05-26 1996-11-28 Bayer Ag Nasal-Applikator
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
US6384016B1 (en) 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
EP1064102B1 (fr) 1998-03-10 2003-11-26 Valois S.A.S. Reservoir, procede de remplissage du reservoir et dispositif de distribution de la poudre contenue dans le reservoir
WO1999047160A1 (en) 1998-03-13 1999-09-23 Novo Nordisk A/S Stabilized aqueous peptide solutions
FR2817847B1 (fr) 2000-12-08 2003-03-28 Tebro Dispositif de distribution de produit fluide ou pulverulent
MXPA06003830A (es) 2003-10-09 2006-07-03 Bioactis Ltd Aparato para abastecer medicina pulverizada para la cavidad nasal.
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
JP2009518315A (ja) * 2005-12-02 2009-05-07 エムディーアールエヌエー，インコーポレイテッド グルコース調節ペプチドの上皮透過性を増大させるための製剤処方
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
EP2370460B1 (en) 2008-12-15 2014-04-30 Zealand Pharma A/S Glucagon analogues
MA32970B1 (fr) 2008-12-15 2012-01-02 Zealand Pharma As Analogues du glucagon
CA2747197A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
UA104766C2 (ru) 2009-07-13 2014-03-11 Зіленд Фарма А/С Ацилированные аналоги глюкагона
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
US9610329B2 (en) 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
JP2013523620A (ja) 2010-03-26 2013-06-17 ノヴォ ノルディスク アー／エス 新規のグルカゴンアナログ
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
CN103068841A (zh) 2010-06-24 2013-04-24 西兰制药公司 胰高血糖素类似物
KR20140114845A (ko) 2011-12-23 2014-09-29 질랜드 파마 에이/에스 글루카곤 유사체
EP3248642B1 (en) 2012-06-28 2020-04-08 The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services Nasal dry powder delivery system for vaccines and other treatment agents
FI124134B (en) 2012-07-02 2014-03-31 One Way Sport Oy Binding between a ski and a ski boot
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
MD3258919T3 (ro) * 2015-02-17 2023-04-30 Lilly Co Eli Formulare de pulbere nazală pentru tratamentul hipoglicemiei

Also Published As

Publication number Publication date
WO2016133863A1 (en) 2016-08-25
PL3258919T3 (pl) 2020-08-10
SI3258919T2 (sl) 2023-01-31
FI3258919T4 (fi) 2023-02-09
CA2975562A1 (en) 2016-08-25
GT201700179A (es) 2018-11-23
PE20171334A1 (es) 2017-09-13
PL3258919T5 (pl) 2023-02-27
DK3258919T3 (da) 2020-03-23
HRP20200222T4 (hr) 2022-12-23
EP3673899A1 (en) 2020-07-01
CN107278154A (zh) 2017-10-20
US20230302093A1 (en) 2023-09-28
MA41547B1 (fr) 2020-04-30
EA034820B1 (ru) 2020-03-25
SI3258919T1 (sl) 2020-03-31
JP2021107418A (ja) 2021-07-29
TN2017000349A1 (en) 2019-01-16
AU2021203035A1 (en) 2021-06-10
CR20170373A (es) 2017-09-18
BR112017014994A2 (pt) 2018-03-20
HUE049413T2 (hu) 2020-09-28
SA517382068B1 (ar) 2020-10-26
MD3258919T3 (ro) 2023-04-30
MY175669A (en) 2020-07-03
DK3258919T4 (da) 2022-11-21
UA121874C2 (uk) 2020-08-10
ES2775498T5 (es) 2023-01-31
EP3258919A1 (en) 2017-12-27
MA52252A (fr) 2021-02-17
BR112017014994B1 (pt) 2023-12-19
PH12017501486A1 (en) 2018-01-15
CN107278154B (zh) 2021-04-09
RS59918B2 (sr) 2023-01-31
US10213487B2 (en) 2019-02-26
AU2021203035B2 (en) 2023-07-13
JP2019147817A (ja) 2019-09-05
IL253273B (en) 2019-08-29
JP6522144B2 (ja) 2019-05-29
MD3258919T2 (ro) 2020-07-31
JP2018507852A (ja) 2018-03-22
JP7362687B2 (ja) 2023-10-17
SG11201705640PA (en) 2017-08-30
HRP20200222T1 (hr) 2020-05-29
NZ734035A (en) 2019-06-28
CO2017008148A2 (es) 2017-11-30
CL2017002031A1 (es) 2018-03-23
EP3258919B2 (en) 2022-11-09
ECSP17053843A (es) 2017-11-30
KR102121443B1 (ko) 2020-06-10
KR20170103934A (ko) 2017-09-13
PT3258919T (pt) 2020-03-26
CY1122716T1 (el) 2021-03-12
ZA201901241B (en) 2020-10-28
JP7094242B2 (ja) 2022-07-01
US20180000904A1 (en) 2018-01-04
DOP2017000179A (es) 2017-08-31
LT3258919T (lt) 2020-02-25
US20190282666A1 (en) 2019-09-19
SV2017005515A (es) 2018-08-27
IL253273A0 (en) 2017-08-31
ES2775498T3 (es) 2020-07-27
AU2016220235A1 (en) 2017-07-20
AU2016220235B2 (en) 2021-04-29
EP3258919B1 (en) 2020-01-15
CA2975562C (en) 2020-04-28
EP3673900A1 (en) 2020-07-01
MX2017010572A (es) 2017-12-07
ZA201704944B (en) 2021-05-26
MA52253A (fr) 2021-02-17
RS59918B1 (sr) 2020-03-31

Similar Documents

Publication Publication Date Title
EA201791560A1 (ru) Порошковый состав для интраназального введения для лечения гипогликемии
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
EP3556858A3 (en) Crispr/cas-related methods and compositions for treating cystic fibrosis
GB2541571A (en) Pharmaceutical compositions
EA201791095A1 (ru) Способ лечения рака
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
ZA201703467B (en) Methods of treating ocular conditions
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
PH12017500275A1 (en) Methods of treating depression using nmda modulators
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EP3636281C0 (en) METHOD FOR TREATING DEPRESSION AND PHARMACEUTICAL COMPOSITION
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2017017119A (es) Formulacion de alta concentracion.
MX2020005557A (es) Agonistas de fxr para el tratamiento de enfermedades hepaticas.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX2016009541A (es) Metodo para tratar vajilla.
GB2567398A (en) Method and composition for treating dysbiosis and related disease states
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.
NZ725354A (en) Transdermal formulations of pergolide and uses thereof